(Total Views: 351)
Posted On: 12/17/2019 9:15:05 AM
Post# of 1460
Did you catch this in the PR yesterday?
Enrollment for the Phase 2 ANAVEX®2-73 (blarcamesine) Parkinson’s disease dementia (PDD) study[4] is expected to be completed by the end of December 2019 with top-line data expected mid-2020. To offer all participants of the study access to ANAVEX®2-73 (blarcamesine), a voluntary 48-week open-label extension, including microbiome assessment, was initiated and currently 100% of eligible participants have opted into the extension study.
So 2 weeks to go for complete enrollment....if this trial is successful, that could be significant news and why would 100% elect to continue the extension study if there was not some benefit?
Enrollment for the Phase 2 ANAVEX®2-73 (blarcamesine) Parkinson’s disease dementia (PDD) study[4] is expected to be completed by the end of December 2019 with top-line data expected mid-2020. To offer all participants of the study access to ANAVEX®2-73 (blarcamesine), a voluntary 48-week open-label extension, including microbiome assessment, was initiated and currently 100% of eligible participants have opted into the extension study.
So 2 weeks to go for complete enrollment....if this trial is successful, that could be significant news and why would 100% elect to continue the extension study if there was not some benefit?
(2)
(0)
